Northwestern Mutual Wealth Management’s Monte Rosa Therapeutics GLUE Stock Holding History

Northwestern Mutual Wealth Management’s Portfolio GLUE Stock Details GLUE Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-300	Closed	-$1.39K	–	3801
2025 Q1	$1.39K	Hold	300	–	–	﹤0.01%	3230
2024 Q4	$2.08K	Hold	300	–	–	﹤0.01%	3169
2024 Q3	$1.59K	Hold	300	–	–	﹤0.01%	3167
2024 Q2	$1.12K	Hold	300	–	–	﹤0.01%	3204
2024 Q1	$2.12K	Hold	300	–	–	﹤0.01%	3034
2023 Q4	$1.7K	Hold	300	–	–	﹤0.01%	3086
2023 Q3	$1.44K	Hold	300	–	–	﹤0.01%	2998
2023 Q2	$2.06K	Hold	300	–	–	﹤0.01%	2980
2023 Q1	$2.34K	Hold	300	–	–	﹤0.01%	2912
2022 Q4	$2.28K	Hold	300	–	–	﹤0.01%	2928
2022 Q3	$2K	Hold	300	–	–	﹤0.01%	2874
2022 Q2	$3K	Hold	300	–	–	﹤0.01%	2835
2022 Q1	$4K	Hold	300	–	–	﹤0.01%	2792
2021 Q4	$6K	Hold	300	–	–	﹤0.01%	2727
2021 Q3	$7K	Buy	+300	New	+$8.6K	﹤0.01%	2569

Other funds holding GLUE

NMC

NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return

VVM

Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

BBA

Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

ACA

Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return

SCM

Suvretta Capital Management New York $3.92B AUM 86.67% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Northwestern Mutual Wealth Management's GLUE Position: Q2 2025 in Review

Northwestern Mutual Wealth Management sold out of Monte Rosa Therapeutics (GLUE) in Q2 2025, closing a stake of 300 shares — an estimated $1.39K sold.

Northwestern Mutual Wealth Management first reported a position in GLUE in Q3 2021 and held it in 15 quarters. The position peaked at $7K in Q3 2021. 116 funds tracked by Wall St. Rank hold GLUE as of Q2 2025.

Northwestern Mutual Wealth Management reported no remaining Monte Rosa Therapeutics position as of Q2 2025 after selling out during the quarter.
Northwestern Mutual Wealth Management sold 300 Monte Rosa Therapeutics shares in Q2 2025, an estimated $1.39K.
Northwestern Mutual Wealth Management first reported a position in Monte Rosa Therapeutics in Q3 2021 and held it in 15 quarters.
Northwestern Mutual Wealth Management's Monte Rosa Therapeutics position peaked at $7K in Q3 2021.
116 funds tracked by Wall St. Rank held Monte Rosa Therapeutics as of Q2 2025.

Based on Northwestern Mutual Wealth Management's 13F filing for Q2 2025, filed 13 Aug 2025.